Based on the encouraging results achieved in the 2025 study, a significantly larger programme is underway in 2026.
Over 30 Clubs are participating in what will be one of the world’s most comprehensive concussion-related clinical trials, in conjunction with the Royal Adelaide Hospital.
Results are expected November 2026.
Clubs
Players
Concussion Trials
Results Expected
Footballers, who are enrolled in this trial of a demonstrably safe, promising treatment for concussion, will be cared for in a world-leading unit at the RAH with access to expertise in both patient care and clinical trials.
In 2025, Spark facilitated a clinical trial on behalf of US based Astrocyte Pharmaceuticals, who have developed a breakthrough concussion drug designed to preserve and protect brain function at the cellular level, limiting the short and long term damage that can occur after head impact.
The ground breaking new study focussed on harnessing the Astrocyte cells unique natural function to protect and repair the brain after injury and measured outcomes of the treatment in impacting players brain biomarkers, symptom recovery and the ability to preserve brain cells during injury.
30 Adelaide based football clubs competing in the Adelaide Football League participated in the study, with over 3000 players receiving concussion education as part of their involvement in the study. Concussed players were invited to enter a research facility overnight where the treatment was administered within 6 hours of the injury occurring.
The players then returned for follow up assessment on days 2, 6, 13 and 20 to assess the players brain biomarkers and symptom recovery.
Clubs
Players
Overnight Treatment
Days 3, 7, 14, 21
